ArticleBMC infectious diseases2026
Clinical characteristics, treatment outcomes, and risk factors for mortality in post-neurosurgical central nervous system infections caused by Acinetobacter baumannii: a retrospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-neurosurgical central nervous system infections (PCNSIs) caused by Acinetobacter baumannii pose a significant therapeutic challenge; however, comprehensive studies focusing on this specific scenario are limited. This study aims to analyze the clinical characteristics, treatment outcomes, and prognostic factors of patients with PCNSIs caused by Acinetobacter baumannii.
methodsA retrospective cohort study was conducted at Guangdong Sanjiu Brain Hospital from January 2020 to June 2025. Patients diagnosed with Acinetobacter baumannii PCNSIs were included and stratified into carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-susceptible Acinetobacter baumannii (CSAB) groups. Clinical data, treatment regimens, and outcomes were analyzed. The primary outcome was 28-day all-cause mortality. Variables selected by LASSO regression were entered into univariate and multivariate Firth's logistic regression models to identify risk factors associated with mortality.
resultsA total of 47 cases were included in the study, with 37 (78.7%) attributed to CRAB and 10 (21.3%) to CSAB. The 28-day mortality rate for CRAB infections was 37.8% (14/37), while no deaths occurred in the CSAB group (P = 0.022). In the CRAB group, Kaplan-Meier analysis indicated that non-polymyxin B-based regimens were associated with significantly higher mortality (70.5%) compared to polymyxin B-based regimens (10.0%; P < 0.001). Univariate analysis revealed that drainage performed following infection (OR = 0.087, 95% CI:0.008-0.502, P = 0.005), polymyxin B-based regimen (OR = 0.059, 95% CI:0.009-0.274, P < 0.001) and mechanical ventilation (OR = 4.399, 95% CI:1.127-19.002, P = 0.033) differed significantly between the groups. Multivariate analysis identified polymyxin B-based regimen as an independent factor associated with lower 28-day mortality (OR = 0.075, 95% CI: 0.008-0.402, P = 0.002).
conclusionCRAB-related PCNSIs are associated with significantly higher mortality compared to CSAB infections. Polymyxin B-based therapy may be associated with improved survival outcomes, while mechanical ventilation may be associated with an increased risk of mortality, warranting heightened clinical vigilance. Although post-infection drainage showed a protective effect in univariate analysis, it did not retain statistical significance as an independent predictor in the multivariable model, suggesting only a potential benefit that requires further validation.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.